An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis (DEFINE): A Phase Ib/IIa Randomised Controlled Trial
16 Aug 2022 in American Journal of Respiratory and Critical Care Medicine
DOI: https://doi.org/10.1164/rccm.202203-0477OC
Research output: Contribution to Journal › Article (E-pub ahead of print)
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
(12 pages) 8 Aug 2022 in Frontiers in pharmacology, vol. 13
DOI: https://doi.org/10.3389/fphar.2022.949264
Research output: Contribution to Journal › Article (Published)
Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation
27 May 2022 in Nature Immunology
DOI: https://doi.org/0.1038/s41590-022-01216-z
Research output: Contribution to Journal › Article (Published)
Hypoxia shapes the immune landscape in lung injury promoting inflammation persistence
(53 pages) 12 Mar 2022, pp. 1-53
DOI: https://doi.org/10.1101/2022.03.11.483935
Research output: › Preprint (Published)
Candidate Role for Toll-like Receptor 3 L412F Polymorphism and Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
1 Mar 2022 in American Journal of Respiratory and Critical Care Medicine, vol. 205, pp. 550-562
DOI: https://doi.org/10.1164/rccm.202010-3880OC
Research output: Contribution to Journal › Article (Published)